# Real-World Experience in the Treatment of Biofilm-Associated Wounds Using Medical-Grade Honey: A Retrospective Case Series

**Authors:** Yun-Nan Lin

PMC · DOI: 10.3390/antibiotics15020150 · Antibiotics · 2026-02-02

## TL;DR

Medical-grade honey helped heal most biofilm-related wounds in a small study, showing promise as an alternative treatment.

## Contribution

Demonstrates clinical effectiveness of medical-grade honey in treating biofilm-associated wounds in real-world settings.

## Key findings

- Eight out of ten biofilm-associated wounds achieved complete healing with medical-grade honey.
- Most wounds showed reduced exudate and inflammation, along with tissue regeneration.
- Two wounds did not fully heal, suggesting variability in treatment response.

## Abstract

Background/Objectives: Wounds complicated by biofilm formation remain a major challenge in wound management. Medical-grade honey (MGH) possesses potent antimicrobial and biofilm-disrupting properties. This study aimed to evaluate the clinical effectiveness of MGH in the treatment of biofilm-associated wounds. Methods: A retrospective case series was conducted involving ten patients with biofilm-suspected wounds treated at Kaohsiung Medical University Hospital and Wesing Hospital. All wounds exhibited positive bacterial cultures and clinical signs of biofilm formation. MGH was applied topically, and wound progression was monitored throughout the treatment period. Results: Eight out of ten wounds achieved complete healing, with a median healing time of 16 weeks (range: 4–46 weeks). Most wounds demonstrated reduced exudate and inflammation, along with progressive granulation and epithelialization. Two wounds did not fully heal within the follow-up period. Conclusions: MGH appears to be a promising adjunctive therapy for wounds associated with biofilm formation, particularly in cases refractory to conventional antibiotic therapy. Further large-scale, controlled studies are warranted to confirm these preliminary findings.

## Full-text entities

- **Diseases:** infected wounds (MESH:D014946), infected ulcers (MESH:D014456), infected (MESH:D007239), diabetic foot infection (MESH:D017719), WS (MESH:D003428), metastasis (MESH:D009362), heel pressure ulcers (MESH:D003668), neuropathy (MESH:D009422), erythema (MESH:D004890), plantar ulcer (MESH:D016523), necrosis (MESH:D009336), tenderness (MESH:D063806), heart disease (MESH:D006331), peripheral arterial disease (MESH:D058729), type II diabetes mellitus (MESH:D003924), breast cancer (MESH:D001943), ischemic necrosis (MESH:D005271), inflammatory edema (MESH:D004487), DM (MESH:D009223), renal failure (MESH:D051437), chronic venous insufficiency (MESH:D014689), diabetes (MESH:D003920), cancer (MESH:D009369), ankle fasciitis (MESH:D005208), pain (MESH:D010146), Wounds (MESH:D014947), leg ulcer (MESH:D007871), uremia (MESH:D014511), inflammation (MESH:D007249), gallbladder stones (MESH:D005705), MGH (MESH:D000069279), oral cancer (MESH:D009062), venous leg ulcers (MESH:D014647), ankle ulcer (MESH:D016512)
- **Chemicals:** L-Mesitran (-), hydrogen peroxide (MESH:D006861), xylitol (MESH:D014993), iodine (MESH:D007455), EDTA (MESH:D004492), doxycycline (MESH:D004318), methicillin (MESH:D008712), pyocyanin (MESH:D011710), silver (MESH:D012834), levofloxacin (MESH:D064704), PHMB (MESH:C031233)
- **Species:** Homo sapiens (human, species) [taxon 9606], Staphylococcus aureus (species) [taxon 1280], Achromobacter xylosoxidans (species) [taxon 85698], Streptococcus agalactiae (species) [taxon 1311], Pseudomonas aeruginosa (species) [taxon 287], Bacteroides sp. (species) [taxon 29523], Enterococcus faecalis (species) [taxon 1351]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12937193/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12937193/full.md

## References

40 references — full list in the complete paper: https://tomesphere.com/paper/PMC12937193/full.md

---
Source: https://tomesphere.com/paper/PMC12937193